Drug Trial Radar · NCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Nov 2, 2027
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Conditions
- Carcinoma, Renal Cell
- Advanced Renal Cell Carcinoma
- Renal Cancer
- Renal Neoplasm
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell Metastasis
- Advanced or Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell, Advanced
- Metastatic Renal Cell Cancer
- Metastatic Renal Cell Carcinoma ( mRCC)
- Metastatic/Advanced Renal Cell Carcinoma
Interventions
PF-08634404Drug
Concentrate for solution for infusion
IpilimumabDrug
Solution for infusion
AxitinibDrug
Tablet
CasdatifanDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigatorTime frame: Up to approximately 3 years
- Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through 90 days after the last study intervention (Up to approximately 3 years)
- Number of participants with dose limiting toxicity (DLT)Time frame: Though end of DLT evaluation period (Up to approximately 3 years)
Locations
183 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic Building- Phoenix
Phoenix, Arizona · Recruiting
Mayo Clinic Arizona
Scottsdale, Arizona · Recruiting
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group
Rogers, Arkansas · Recruiting
Highlands Oncology Group, PA
Springdale, Arkansas · Recruiting
UCLA Hematology/Oncology - Alhambra
Alhambra, California · Not yet recruiting
UCLA Hematology/Oncology - Atascadero
Atascadero, California · Not yet recruiting
UCLA Hematology/Oncology - Burbank
Burbank, California · Not yet recruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California · Recruiting
City of Hope Investigational Drug Services (IDS)
Duarte, California · Recruiting
UC San Diego Medical Center - Encinitas
Encinitas, California · Recruiting
UCLA Hematology/Oncology- Encino
Encino, California · Not yet recruiting
UCLA Hematology/Oncology- Irvine
Irvine, California · Not yet recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Investigational Drug Services (IDS)
Irvine, California · Recruiting
UC San Diego / Moores Cancer Center
La Jolla, California · Recruiting
UC San Diego Koman Family Outpatient Pavilion
La Jolla, California · Recruiting
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California · Recruiting
UC San Diego Sulpizio Cardiovascular Center
La Jolla, California · Recruiting
UCLA Hematology/Oncology - Laguna Hills
Laguna Hills, California · Not yet recruiting
City of Hope
Long Beach, California · Recruiting
Investigational Drug Services, Bowyer Pharmacy
Los Angeles, California · Not yet recruiting
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California · Not yet recruiting
UCLA Hematology/Oncology
Los Angeles, California · Not yet recruiting
UCLA Hematology/Oncology - Marina del Rey
Marina del Rey, California · Not yet recruiting
UCLA Hematology/Oncology - Pasadena
Pasadena, California · Not yet recruiting
UCLA Hematology/Oncology - Porter Ranch
Porter Ranch, California · Not yet recruiting
UC San Diego Medical Center - Bankers Hill
San Diego, California · Recruiting
UC San Diego McGrath Outpatient Pavilion - Hillcrest
San Diego, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
UC San Diego Medical Center - Rancho Bernardo
San Diego, California · Recruiting
UCLA Hematology/Oncology - San Luis Obispo
San Luis Obispo, California · Not yet recruiting
UCLA Hematology/Oncology- Santa Barbara
Santa Barbara, California · Not yet recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Not yet recruiting
UCLA Hematology/Oncology- Torrance
Torrance, California · Not yet recruiting
City of Hope UPLAND
Upland, California · Recruiting
UCLA Hematology/Oncology - Santa Clarita
Valencia, California · Not yet recruiting
UCLA Hematology/Oncology- Ventura
Ventura, California · Not yet recruiting
UC San Diego Medical Center - Vista
Vista, California · Recruiting
UCLA Hematology/Oncology- Westlake
Westlake Village, California · Not yet recruiting
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.